EGFR and neoplasm: These non-mutant selective studies demonstrated that clinical factors are less predictive of responsiveness than tumor genetics and provide very strong justification for upfront testing if first-line EGFR therapy is contemplated since clinically selected but EGFR WT patients appear to fare dramatically worse on gefitinib than chemotherapy.